Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.

Inclusion Criteria: * Participants with relapsed or refractory CD5+ NK and T-cell originated malignancies (per WHO classification 2017). * Participants with relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any treatment option considered as assessed by the Investigator. * According to the Lugano classification, Participants having lesion/nodules ≥ 1 with diameter longer than 1.5 cm for nodal lesions and longer than 1.0 cm for extranodal lesions, and the boundaries are clearly shown. * Participant has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status. * Participants who satisfy the criteria defined in the protocol. * Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Participants who comply with all procedures of this study and voluntarily give written consent Exclusion Criteria: * Has T-ALL/T-LBL, CTCL or ALCL. * Participants with CNS lymphoma or any involvement of the CNS. * Participants who had a prior history of another malignancy over the last 3 years. * Participants who have used hematopoietic growth factor therapy within 14 days prior to Screening. * Participants who have had prior CAR-T or CAR-NK therapies. * Presence of uncontrolled fungal, bacterial, viral infection or other infection requiring IV antimicrobials for management * Participants with previous allogenic organ transplantation * Participants with previous diagnosis of primary immunodeficiency or currently undergoing therapy of primary immunodeficiency. * Participants with acute GvHD ≥ Grade 3 or extensive chronic GvHD within 2 weeks of lymphodepletion. * Participants with known active Hepatitis B or C * Participants with presence of Grade 2 or greater toxicity from the previous treatment.